[Federal Register Volume 61, Number 184 (Friday, September 20, 1996)]
[Notices]
[Page 49472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-24147]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Advisory Committee Meeting; Postponement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is postponing the 
meeting of the Antiviral Drugs Advisory Committee scheduled for 
September 26 and 27, 1996. The meeting was announced by a notice in the 
Federal Register of September 4, 1996 (61 FR 46652). This meeting is 
being postponed to allow time to incorporate the results of additional 
study information which have recently become available for the new drug 
application 20-705, delavirdine (Rescriptor, Pharmacia and 
Upjohn Co.) for use in the treatment of human immunodeficiency virus 
(HIV) infection. The meeting will be rescheduled at a later date and 
will be announced in the Federal Register.

FOR FURTHER INFORMATION CONTACT: Rhonda W. Stover, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-443-5455; or call the FDA 
Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), Antiviral Drugs Advisory Committee, code 
12531.

    Dated: September 13, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-24147 Filed 9-19-96; 8:45 am]
BILLING CODE 4160-01-F